Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633 1643 1651
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17433887 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18282645 | METHODS AND MATERIALS FOR TREATING PROPIONIC ACIDEMIA | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 19041656 | METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS | Final Rejection | Helix Nanotechnologies Inc |
| 18406066 | FANZORS ARE RNA-GUIDED NUCLEASES ENCODED IN EUKARYOTIC GENOMES | Final Rejection | Massachusetts Institute of Technology |
| 18163253 | Methods and Compositions to Target and Treat Macrophages | Non-Final OA | Massachusetts Institute of Technology |
| 17764917 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 17580190 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 18372374 | METHOD OF PRODUCING A CELL POPULATION COMPRISING AN AMNION-DERIVED MESENCHYMAL STEM CELL | Non-Final OA | KANEKA CORPORATION |
| 18368130 | Rat models for CMT2A that develop a progressive neuropathy | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17756104 | LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF B CELLS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17755887 | LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF NK CELLS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18484667 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Non-Final OA | THE TEXAS A&M UNIVERSITY SYSTEM |
| 18981653 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | Non-Final OA | INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES |
| 18980456 | Targeted CRISPR Delivery Platforms | Final Rejection | University of Massachusetts |
| 18049724 | COMPLEXES FOR GENE DELETION AND EDITING | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18036488 | SALICYLIC ACID-INDUCIBLE GENE EXPRESSION COMPOSITIONS AND SYSTEMS FOR CELLS | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 17911041 | A MIXTURE OF MRNA TO ENHANCE THE POTENCY OF DENDRITIC CELLS | Non-Final OA | Vrije Universiteit Brussel |
| 17954674 | MODIFIED GRAFTS | Non-Final OA | Musculoskeletal Transplant Foundation |
| 17164624 | Programmable Designer Therapeutic Fusogenic Secreted Gectosome Vesicles For Macromolecule Delivery And Genome Modification | Final Rejection | The Regents of the University of Colorado, a body corporate |
| 17934501 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | Final Rejection | Baylor College of Medicine |
| 18486731 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | Non-Final OA | FIGENE, LLC |
| 18176500 | RECOMBINANT DGKK GENE FOR FRAGILE X SYNDROME GENE THERAPY | Non-Final OA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE |
| 17742724 | HYBRID NUCLEIC ACID MOLECULES AND THEIR USE | Final Rejection | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE |
| 16098918 | DNA Monoclonal Antibodies Targeting IL-6 and CD126 | Final Rejection | The Wistar Institute of Anatomy and Biology |
| 18271715 | METHOD FOR CULTURING HUMAN HEPATIC PARENCHYMAL CELL, CULTURED HUMAN HEPATIC PARENCHYMAL CELL, CULTURE MEDIUM AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CULTURE SUPERNATANT OF HUMAN HEPATIC NONPARENCHYMAL CELL | Non-Final OA | JSR CORPORATION |
| 17674378 | INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY | Final Rejection | The U.S.A., as Represented by the Secretary, Department of Health and Human Services |
| 18158310 | CELL | Non-Final OA | AUTOLUS LIMITED |
| 18065464 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | Non-Final OA | KSQ Therapeutics, Inc. |
| 18217401 | Sialylated Glycoproteins | Non-Final OA | Momenta Pharmaceuticals, Inc. |
| 17792960 | TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) | Final Rejection | REGENXBIO RS LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy